OncoBeta

OncoBeta is a medical device company that has developed and commercializes an epidermal radioisotope therapy for non-melanoma skin cancers, such as basal cell and squamous cell carcinomas. The company's flagship product is the Rhenium-SCT (Skin Cancer Therapy), a non-invasive treatment that utilizes the beta-emitter radioisotope Rhenium-188. This isotope is applied directly to the lesion as a paste, offering a targeted therapy with a high-energy beta emission.

OncoBeta manages the production of the Rhenium-188 through its own Tungsten-188/Rhenium-188 Generators. The company's business model involves providing the complete Rhenium-SCT system, which includes the radioisotope compound and specially designed applicators, to healthcare facilities. It targets hospitals and specialized clinics, training medical personnel on the proper use of the therapy. The company is expanding its operations globally, with a presence in Europe, South Africa, and Australia, and is actively working to make its treatment available to more patients by partnering with hospitals.

Keywords: epidermal radioisotope therapy, non-melanoma skin cancer, Rhenium-SCT, medical devices, oncology, Rhenium-188, targeted therapy, dermatology, nuclear medicine, brachytherapy